Form 424B5 - Prospectus [Rule 424(b)(5)]:
SEC Accession No. 0001193125-26-192361
Filing Date
2026-04-29
Accepted
2026-04-29 17:28:35
Documents
14

Document Format Files

Seq Description Document Type Size
1 424B5 d37532d424b5.htm 424B5 460203
2 EX-FILING FEES d37532dexfilingfees.htm   iXBRL EX-FILING FEES 18677
3 GRAPHIC g37532g01g01.jpg GRAPHIC 34512
4 GRAPHIC g37532g04g04.jpg GRAPHIC 27477
5 GRAPHIC g37532g67g67.jpg GRAPHIC 39051
  Complete submission text file 0001193125-26-192361.txt   740828

Data Files

Seq Description Document Type Size
18 EXTRACTED XBRL INSTANCE DOCUMENT d37532dexfilingfees_htm.xml XML 4725
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B5 | Act: 33 | File No.: 333-275740 | Film No.: 26918237
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)